Brainomix

Brainomix develops artificial intelligence imaging software to assist clinicians in stroke and lung fibrosis care.

Oxford, UK—Founded 2010—Website

£20.8MTotal raised

Brainomix is a medical imaging company that develops artificial intelligence tools to improve diagnosis and treatment decisions for stroke and lung fibrosis. The firm spun out from the University of Oxford and operates in more than twenty countries.

Founders

Michalis Papadakis

CEO

Investors

Series C24 February 2026
£4.8M
ParkwalkLead
H
HostplusLead
MV
Modi Ventures
Series B16 December 2021
£16.0M
Boehringer Ingelheim Venture FundLead
Parkwalk AdvisorsLead
Tencent
OU
Oxford University Innovation Fund

Funding history

Series C24 February 2026

£4.8M

Brainomix secures £4.8m Series C extension led by Parkwalk and Hostplus to fund US growth

The extension brings total Series C financing to £18.8m with participation from US investor Modi Ventures.

Series B16 December 2021

£16.0M

Brainomix raises £16m in Series B funding from Boehringer Ingelheim Venture Fund and Parkwalk Advisors to expand into new therapeutic indications.

The financing round was co-led by Boehringer Ingelheim Venture Fund and Parkwalk Advisors, with participation from Tencent and Oxford University Innovation Fund.